Esketamine implementation challenges in psychiatry: A qualitative analysis of mental healthcare providers' social media commentary

Abstract

Background Though esketamine was approved by the Food and Drug Administration (FDA) for treatment-resistant depression in 2019, there is no published research on implementation challenges. Therefore, the aim of this study was to investigate online commentary about these challenges among mental healthcare providers. Methods Using the terms "esketamine" and "Spravato", the author searched social media groups dedicated to mental healthcare providers on December 15, 2022. Posts and associated comments about using or implementing esketamine into practices were included in the dataset and thematically coded. Prevalence of themes about implementation challenges, illustrative quotes, and sentiment analyses are reported. Results 186 relevant posts and comments from March 12, 2019 to November 27, 2022 were identified. The most discussed challenges were billing/reimbursement (65.1%), billing codes (48.9%), staffing (18.3%), pharmacy/drug procurement (16.7%), space (11.8%), time (10.2%), "Buy and bill" acquisition (9.1%), and the FDA Risk Evaluation and Mitigation Strategy (REMS) program (7%). Sentiment regarding reimbursement for esketamine was mostly negative [72.3% (34/47 posts)], as was sentiment towards esketamine's manufacturer (62.5% (5/8 posts). Most posts [86.7% (13/15 posts)] comparing esketamine to ketamine favored using ketamine. Conclusions These data suggest that under-reimbursement, billing challenges, and logistical barriers may be hamstringing implementation of esketamine into psychiatric practices.

Competing Interest Statement

Brian Barnett reports a relationship with CB Therapeutics that includes: board membership and equity or stocks. Brian Barnett reports a relationship with COMPASS Pathways Plc that includes: board membership. Brian Barnett reports a relationship with Mind Medicine Inc. that includes: funding grants. Brian Barnett reports a relationship with EBSCO Industries Inc that includes: consulting or advisory. Brian Barnett reports a relationship with Cerebral that includes: consulting or advisory. Brian Barnett reports a relationship with Janssen Pharmaceuticals that includes: consulting or advisory.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was declared exempt by the Cleveland Clinic Institutional Review Board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Comments (0)

No login
gif